PEVIA Consortium Submits 1st Intermediate Report
Evry, 1stAugust 2018 – The PEVIA consortium, created by Vaxeal,today announced that they have successfully reached their first milestones,including the design and production of near native recombinant ZEBOLA Glycoprotein (GP) and Long Synthetic Peptide (LSP)-based vaccine candidates against EBOV for pre-clinical and clinical studies, and submitted the 1st intermediate report to Innovative Medicines Initiative (IMI).
PEVIA - Pan-Ebola Vaccine Innovative Approach - is a collaborative research project aiming to develop and to bring to the clinics an innovative pan-Ebola vaccine, safe and effective against multiple Ebola virus strains and ease to produce and deploy in endemic regions. This project, officially kicked off on October 4st 2017, also focuses on the development of innovative functional analysis tools to accelerate the development of new vaccine candidates against EBOV and other Filovirus, and diagnostic tests. PEVIA project expects to bring a significant impact on global health and to increase the readiness to respond to future outbreaks of Ebola and other filoviral haemorrhagic fevers. PEVIA project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116088. Visit www.PEVIA-Ebola.eufor more information.
Vaxeal Holding SA is headquartered in Vevey, Switzerland, with operations in Evry, France (VAXEAL Research). The company, in partnership with leading international research institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases. The cutting-edge immunotherapies are protected by several patent families and initial programs have reached the pre-clinical stage in major disease segments. Visit www.vaxeal.net for more information.
About the Innovative Medicines Initiative (IMI)
The Innovative Medicines Initiative (IMI) is a public-private partnership (PPP) between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). IMI is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.Visitwww.imi.europa.eufor more information.
PEVIA project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116088. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, and EFPIA.